{"id":476575,"date":"2020-03-27T12:36:01","date_gmt":"2020-03-27T12:36:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=476575"},"modified":"2020-03-27T12:36:01","modified_gmt":"2020-03-27T12:36:01","slug":"pruritus-companies-assessment-report-2020-emerging-drugs-and-competitive-landscape","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/pruritus-companies-assessment-report-2020-emerging-drugs-and-competitive-landscape_476575.html","title":{"rendered":"Pruritus Companies Assessment Report, 2020: Emerging drugs and Competitive landscape"},"content":{"rendered":"
\"Pruritus<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
“Pruritis Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Pruritis market. A detailed picture of the Pruritis pipeline landscape is provided, which includes the disease overview and Pruritis treatment guidelines. <\/div>\n

“Pruritis Pipeline Insight, 2020<\/a>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Pruritis market. A detailed picture of the Pruritis pipeline landscape is provided, which includes the disease overview and Pruritis treatment guidelines. The assessment part of the report embraces in-depth Pruritis commercial assessment and clinical assessment of the Pruritis pipeline products from the pre-clinical developmental phase to the marketed phase. <\/p>\n

Pipeline Development Activities: <\/p>\n

<\/strong>The report provides insights into:
1. All of the companies that are developing therapies for the treatment of Pruritis with aggregate therapies developed by each company for the same.
2. Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Pruritis treatment.
3. Pruritis key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
4. Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
5. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Pruritis market.<\/p>\n

The report is built using data and information traced from the researcher’s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third-party sources, etc.  <\/p>\n

\"\"<\/strong><\/p>\n

View report<\/strong>: https:\/\/www.delveinsight.com\/sample-request\/pruritis-pipeline-insight<\/p>\n

“The females give higher itch ratings than males.”<\/strong><\/p>\n

The key pharma players involved in Pruritis market are:<\/strong>
1. Menlo Therapeutics
2. Cara Therapeutics<\/p>\n

The launch of the emerging therapies is expected to significantly impact Pruritis treatment scenario in the upcoming years:-<\/strong>
Drugs covered:<\/strong>
1. Serlopitant
2. CR845<\/p>\n

Highlights of the report:<\/strong>
1. A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Pruritis.   
2. In the coming years, the Pruritis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
3. The companies and academics that are working to assess challenges and seek opportunities that could influence Pruritis R&D. The therapies under development are focused on novel approaches to treat\/improve the disease condition.
4. A detailed portfolio of major pharma players who are involved in fueling the Pruritis treatment market. Several potential therapies for Pruritis are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Pruritis market size in the coming years. 
5. Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Pruritis) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. <\/p>\n

Table of contents:<\/strong>
1. Report Introduction
2. Pruritis
3. Pruritis Current Treatment Patterns
4. Pruritis – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Pruritis Late Stage Products (Phase-III)
7. Pruritis Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pruritis Discontinued Products
13. Pruritis Product Profiles
14. Pruritis Key Companies
15. Pruritis Key Products
16. Dormant and Discontinued Products
17. Pruritis Unmet Needs
18. Pruritis Future Perspectives
19. Pruritis Analyst Review 
20. Appendix
21. Report Methodology<\/p>\n

About DelveInsight:
<\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Vinita Rakheja
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP “Pruritis Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Pruritis market. A detailed picture of the Pruritis pipeline landscape is provided, which includes the disease … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-476575","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/476575","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=476575"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/476575\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=476575"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=476575"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=476575"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}